Vedolizumab for treating moderately to severely active ulcerative colitis

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: equality impact assessment - guidance review

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final appraisal determination information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final appraisal determination document

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final appraisal determination document (PDF 452 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: committee papers information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: appraisal consultation

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: appraisal consultation document

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: appraisal consultation document (PDF 684 KB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: evaluation report and supporting information information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 1 information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 1 (PDF 5.64 MB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 2 information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 2 (PDF 5.23 MB)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 3 information

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: equality impact assessment form (post referral)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: NICE response to consultee and commentator comments on the draft scope and provisional matrix (post-referral)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final matrix (post-referral)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final scope (post-referral)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: draft scope for consultation (pre-referral) - August 2013

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: provisional matrix (pre-referral) - August 2013